Financials
- Fiscal year
- 2025
- Total assets
- €57,363
- Profit
- €44,708
- Solvency
- 83.2%
MB Pharmaceutics
ActiveSummary
The computed 12-month bankruptcy probability of MB Pharmaceutics is 3.0% (moderate). The 2025 annual accounts show equity of €47,708 and a net result of €44,708. Its solvency ranks better than 91% of 11770 sector peers (fiscal year 2025). The company has been active since 2024 and the Belgian State Gazette contains no insolvency or warning signals.
Overview
Activity
Retail sale of pharmaceutical products
NACE 47730
1 site
Size
€57,363total assets 2025
- Equity
- €47,708
- Profit
- €44,708
Turnover not published (abridged schema)
Structure
Accounts 43 d early0 of 1 deed read
Why 50- Founded in 2024- Sector Retail trade (NACE 47)Show the evidence
Checked score
Score 2025
50
/ 100
Fair
Probability in this band: 1.5% to 4.2%
Place in the band from the probability alone: no sector peers known
Financial strength
Strong
Solvency
100
equity 83.2% of total assets
Liquidity
96
short-term debt 16.8% · cash 56.2%
Profitability
100
return on assets 77.9%
Bankruptcy probability, 12 months
3.0%
Moderate
0%0.5%1.5%4%10%≥ 25%
About 3 in 100 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2025: 1.8%lowest value
01-2026: 1.8%● 0.0% vs 12-2025lowest value
02-2026: 1.9%▲ +4.8% vs 01-2026
03-2026: 2.2%▲ +16.8% vs 02-2026
04-2026: 2.3%▲ +5.7% vs 03-2026
05-2026: 2.6%▲ +10.3% vs 04-2026
06-2026: 2.6%● 0.0% vs 05-2026
07-2026: 2.9%▲ +10.4% vs 06-2026
08-2026: 2.8%▼ -1.4% vs 07-2026
09-2026: 2.8%▼ -1.1% vs 08-2026
10-2026: 3.0%▲ +8.7% vs 09-2026highest value
- Founded in 2024 raises the probability for this profile
- Sector Retail trade (NACE 47) raises the probability
Credit up to €2,000 at 30 days acceptable
Liquidity ample (current ratio 5.85; short-term debt: 16.8% and cash: 56.2% of total assets), and 16.8% of the assets are financed with debt.
How it is calculated
The band comes from the bankruptcy probability on a scale of 0 to 100: every 10 points more double the odds of getting through the year without bankruptcy.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Place inside the band: from the bankruptcy probability alone, as no sector peers are known.
Bankruptcy probability: model pd-v3.202610021621, computed on 03-10-2026. The model learns from Belgian bankruptcies and reads the registers, the annual accounts and the gazette.
Ceilings: negative or zero equity, a heavy loss, a special KBO legal situation and a missing filing 59 (two missing 44), an ongoing judicial reorganisation or an ending 24. Financial strength does not count in the score.
Credit check for your own amount and term
Show the recommended maximum : and see how the verdict changes with amount, term and advance.
Signals
Three signals. The signal on the left, the evidence on the right.
+raises risk○neutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 18-06-2026, 43 days ahead of the deadline.
NBB · 1 filingDeviation from the deadline
2025
43 d early
← before the deadline
after the deadline →
Checked, nothing found (1)
- Annual accounts filedfiscal year 2025 · abbreviated…
Key points
By topic
Timeline
- Events
- 1
- Since
- 2026
- 18-06-2026Annual accounts filed
Company details
- Sites
- 1
- Legal form
- Private limited company
- Activity
- Retail sale of pharmaceutical productsNACE 47730
- Founded
- 19-11-2024
- Year ends
- 31-12
- Peppol
- Reachable for e-invoices
Go further with this company
How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark Roughly what is this company worth?Value indication
Your own company? See how customers, suppliers and banks see it and what to improve first.
Investigating this company? Keep it with today's facts in a case file.